These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22494933)

  • 1. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
    Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitors in the treatment of breast cancer.
    Vinayak S; Carlson RW
    Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
    Johnston SR
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
    Johnston SR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
    Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting endocrine resistance: is there a role for mTOR inhibition?
    Sheri A; Martin LA; Johnston S
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endocrine therapy resistance in metastatic breast cancer: mechanisms and clinical implications].
    Orcurto A; Odermatt R; Stravodimou A; Wolfer A
    Rev Med Suisse; 2014 May; 10(431):1102-6. PubMed ID: 24941677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
    Chollet P; Abrial C; Tacca O; Mouret-Reynier MA; Leheurteur M; Durando X; Curé H
    Clin Breast Cancer; 2006 Oct; 7(4):336-8. PubMed ID: 17092402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
    Provenzano A; Kurian S; Abraham J
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine therapy: is the first generation of targeted drugs the last?
    Pritchard KI
    J Intern Med; 2013 Aug; 274(2):144-52. PubMed ID: 23844917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
    Johnston SR
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):889s-99s. PubMed ID: 15701883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.